ADTX(ADTX)
ADTX
ANALYST COVERAGE2 analysts
BUY
▲ +248492.0%upside to target
Key MetricsTTM
Market Cap$17.2K
Revenue TTM—
Net Income TTM—
Free Cash Flow—
Gross Margin19.9%
Operating Margin-127821.4%
Net Margin-362385.7%
Return on Equity926.0%
Return on Assets-373.6%
Debt / Equity—
Current Ratio0.06
EPS TTM—
PRICE
Prev Close
1.22
Open
0.79
Day Range0.47 – 0.85
0.47
0.85
52W Range0.47 – 53,453.52
0.47
53,453.52
0% of range
VOLUME & SIZE
Avg Volume
317.1K
FUNDAMENTALS
P/E Ratio
0.0x
Value territory
EPS (TTM)
—
Div Yield
No dividend
Beta
0.52
Low vol
TECHNICAL
RSI (14)
71
Overbought
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 128 days
Sep 28
ADTX News
About
a biotech company with a mission to accelerate humanity’s transition to the "age of immunity", we are the business busily decoding the human immune system.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Rowena AlbannaChief Operating Officer
Ge ChenSenior Vice President of Preclinical Research & Discovery
Thomas J. FarleyChief Financial Officer
Shahrokh ShabahangCo-Founder, Chief Innovation Officer, Secretary & Director
Amro A. AlbannaCo-Founder, Chairman & Chief Executive Officer
Corinne D. PankovcinChief Mergers & Acquisitions Officer
Jennifer LeeDirector of Human Resources
Dolly TyanSenior Vice President of Clinical Development Transplantation
Christopher J. PorcelliGeneral Counsel & Chief People Officer